Scalp Health for Hair Growth: Find the Right Cause First

The direct answer

Hair loss is not one condition, and "improving scalp health" means different things depending on which process is driving the shedding. Androgen-driven miniaturization (androgenetic alopecia), inflammatory or infectious scalp disease (seborrheic dermatitis, tinea capitis, scarring alopecias), and nutritional or stress-related diffuse shedding (telogen effluvium) have different mechanisms and different first-line treatments. Topical minoxidil and oral finasteride have randomized-trial support for androgenetic alopecia specifically; they do nothing to reverse iron-deficiency shedding or a scarring alopecia, and using them while the real cause goes undiagnosed can delay effective treatment, particularly for scarring conditions where delay causes permanent follicle loss. The single most useful diagnostic step before starting any product is identifying the pattern of loss (diffuse versus patterned versus patchy) and, when uncertain, getting a scalp exam and basic labs.

Why scalp health drives hair growth

Each hair grows from a follicle that cycles through three phases: anagen (active growth, roughly 2 to 7 years), catagen (transition, a few weeks), and telogen (resting and shedding, about 3 months). A scalp under chronic inflammation, poor blood flow, or nutritional stress pushes follicles into telogen earlier than they otherwise would, producing diffuse thinning known as telogen effluvium. This is why scalp-level factors, not just genetics, meaningfully affect how hair looks and behaves.

The scalp microbiome and inflammation

The scalp hosts a distinct microbial community, and Malassezia yeast overgrowth is a recognized driver of dandruff and seborrheic dermatitis. Malassezia metabolizes sebum into byproducts that irritate the skin barrier and trigger local inflammation. Chronic low-grade inflammation near the follicle's stem-cell-containing region is plausibly linked to follicle miniaturization, though the degree to which this pathway contributes to androgenetic alopecia specifically, as opposed to inflammatory alopecias, is still being worked out and should not be overstated.

Blood flow to the follicle

Follicles are metabolically demanding tissue, and adequate blood supply delivers the oxygen and nutrients needed during active growth. Minoxidil's proposed mechanism includes vasodilation, which may increase local blood flow and prolong the anagen phase, though minoxidil's exact mechanism in humans is still incompletely understood despite decades of use.

Treatments with the strongest evidence

Minoxidil (topical and oral)

Topical minoxidil is FDA-approved for androgenetic alopecia: 2% solution is approved for women and 5% solution or foam for men. Multiple randomized trials have shown greater hair count increases with minoxidil than placebo over roughly 6 months, though the exact magnitude reported varies by trial and should be checked against the specific study before quoting a number.

Oral minoxidil at low doses (a fraction of the blood-pressure dose) is used off-label for hair loss in both men and women and has become common in dermatology practice because of easier dosing than topical solution. It is not FDA-approved for this indication, and blood pressure should be monitored, particularly in patients with cardiovascular disease.

Apply topical minoxidil to a dry scalp as directed on the label, allow it to dry before styling, and expect several months of consistent use before assessing whether it is working. A temporary increase in shedding in the first 4 to 8 weeks is a commonly reported phenomenon as the drug pushes resting follicles into a new growth cycle; it is not, by itself, a sign of treatment failure, but persistent worsening beyond a few months warrants a check-in with a clinician.

Finasteride and dutasteride

Finasteride 1 mg daily, an oral 5-alpha-reductase type II inhibitor that lowers scalp dihydrotestosterone, is FDA-approved for male-pattern hair loss and has trial evidence showing hair count benefit over placebo at 1 to 2 years. Dutasteride, which inhibits both type I and type II 5-alpha-reductase more completely, is not FDA-approved for hair loss in the United States and is used off-label; some trials have suggested it produces larger hair count gains than finasteride, though comparative data should be reviewed directly before relying on a specific effect size.

Finasteride and dutasteride are contraindicated in people who are pregnant or may become pregnant, because of the risk of abnormal development of a male fetus's external genitalia. Sexual side effects (reduced libido, erectile dysfunction) are reported in a minority of users. A cluster of persistent symptoms after stopping the drug, sometimes called post-finasteride syndrome, has been reported anecdotally; its prevalence and mechanism are not established in prospective controlled research, and this uncertainty should be discussed directly with a prescriber rather than assumed away in either direction.

Ketoconazole shampoo

Ketoconazole shampoo (1% over-the-counter, 2% prescription) reduces Malassezia colonization and has trial evidence of benefit for dandruff and, in some studies, for hair density in androgenetic alopecia, used a few times weekly rather than daily to avoid drying the scalp. It is a reasonable first step for anyone whose shedding is accompanied by scalp scaling, itching, or visible dandruff, independent of whether androgenetic alopecia is also present.

Platelet-rich plasma (PRP)

PRP concentrates a patient's own platelets and injects them into the scalp to deliver growth factors locally. Systematic reviews of randomized trials have generally reported a benefit for hair density compared with control treatments, though trial quality and protocols vary considerably across the literature, and PRP is a procedure performed by a clinician rather than a home treatment, with cost and session frequency that should be confirmed with the provider directly.

JAK inhibitors for alopecia areata

Baricitinib and ritlecitinib are FDA-approved specifically for severe alopecia areata, an autoimmune condition distinct from androgenetic alopecia. These drugs are not appropriate for pattern hair loss and carry systemic immune-modulating risks that require specialist monitoring. Their approval is a meaningful development for alopecia areata specifically and should not be generalized to other causes of hair loss.

Scalp care practices with some trial support

Scalp massage. A small controlled study found that several minutes of daily standardized scalp massage over months increased hair shaft thickness, with a proposed mechanism of mechanical stretching of dermal papilla cells. The evidence base is limited (small sample sizes, short follow-up), so this should be understood as a low-risk adjunct rather than a proven primary treatment.

Washing frequency and shampoo ingredients. Washing too rarely lets sebum and Malassezia accumulate; washing too often can strip the barrier and prompt compensatory oil production. Two to three washes per week is reasonable for most scalp types, with daily gentle washing acceptable for fine, oil-prone hair. Zinc pyrithione and selenium sulfide are reasonable anti-Malassezia alternatives to ketoconazole; salicylic acid and coal tar are standard for scalp psoriasis.

Traction and heat. Traction alopecia results from chronic tension on follicles from tight hairstyles (braids, tight ponytails, extensions) and is a recognized and largely preventable cause of hair loss, especially in women who wear tension-heavy protective styles. Early traction alopecia is reversible if tension is removed; prolonged tension can progress to permanent, scarring loss. Keeping styling-tool heat moderate and alternating tight and loose styles reduces cumulative mechanical stress.

Nutrition: what has evidence, what does not

Iron and ferritin. Iron deficiency is a recognized cause of diffuse shedding in premenopausal women, and clinicians commonly treat low-normal ferritin (below roughly 30 ng/mL) in women with telogen effluvium even without frank anemia. Correcting iron deficiency typically takes several months to show benefit in shedding.

Protein. Hair is largely keratin, a protein, and diets low in protein or in the amino acids needed for keratin synthesis can contribute to diffuse shedding. Specific branded supplement trials exist in the literature, but effect sizes vary by formulation and should be checked against the specific product before assuming benefit.

Biotin. Biotin deficiency causes hair loss but is uncommon in people eating a varied diet. The FDA has warned that biotin supplementation at high doses can interfere with certain lab immunoassays (including troponin and thyroid tests), producing falsely abnormal results that could complicate diagnosis in an emergency setting; this is a genuine safety consideration, not a reason to avoid biotin outright, but it argues against routine high-dose supplementation absent a confirmed deficiency.

Zinc. Low serum zinc has been associated with alopecia areata and telogen effluvium in observational studies, and zinc repletion has shown benefit in at least one placebo-controlled trial. Zinc supplementation at high doses for extended periods can cause copper deficiency, which can itself worsen shedding, so self-dosing above standard supplement levels without lab guidance is not advised.

Vitamin D. Low vitamin D is associated with alopecia areata and female-pattern hair loss in observational data; association does not establish that supplementation reverses hair loss, and this remains an area where the evidence is suggestive rather than definitive.

Lifestyle factors

Chronic stress, poor sleep, and smoking are each plausibly linked to hair-cycle disruption through cortisol, growth-hormone, and vascular mechanisms respectively, and observational data associate smoking with a higher likelihood of moderate-to-severe androgenetic alopecia. These associations are biologically coherent but mostly observational; addressing them is reasonable for overall health regardless of hair outcome, and framing them as a guaranteed fix for hair loss overstates the current evidence.

When to see a clinician

Not all hair loss responds to over-the-counter treatment, and some patterns need prompt evaluation rather than a trial of home products:

• Patchy, round bald spots (possible alopecia areata)
• Scalp redness, scaling, or pustules (possible tinea capitis or folliculitis)
• Visible scarring or permanent-looking bald patches (scarring alopecias need biopsy, and treatment delay risks permanent follicle loss)
• Diffuse shedding that feels dramatically heavier than baseline and persists more than a few months
• Sudden shedding following illness, surgery, rapid weight loss, or a new medication

Dermatology guidance generally recommends a structured workup before starting treatment: history (medications, diet, recent illness, family history), scalp examination, and targeted labs when the diagnosis is unclear. A commonly used lab panel includes ferritin, TSH and free T4, 25(OH)D, zinc, and, in women with signs of androgen excess, DHEA-S and testosterone. A scalp biopsy adds diagnostic precision when the pattern is ambiguous, particularly to distinguish scarring from non-scarring alopecia.

Emerging and adjunct approaches

Low-level laser therapy (LLLT) devices are marketed for androgenetic alopecia based on the idea that red light increases follicle mitochondrial activity; device-specific trial results vary and the exact figures reported for any single device should be verified against that device's own trial data rather than assumed to generalize across products. A related but distinct application, photobiomodulation to prevent chemotherapy-induced alopecia in breast cancer patients, was tested in a randomized controlled trial (2025); this is a different population and a different goal (prevention during chemotherapy) from cosmetic LLLT for pattern hair loss, and the two should not be conflated.

A randomized, placebo-controlled, double-blinded 2025 trial of a topical amaranthus extract reported improved follicle health markers and anagen hair density compared with placebo (Amaranthus Extract Promotes Healthy Follicles and Anagen Hair Density, 2025). This is a single trial of a specific formulation; it does not establish that amaranthus-containing products generally work, and readers should look at the trial's population, duration, and formulation before generalizing to a product on a shelf.

Spironolactone, an aldosterone antagonist with anti-androgen effects, is used off-label for female-pattern hair loss at higher doses than typically used for blood pressure, with some retrospective data suggesting stabilization or improvement in a meaningful share of users; it requires blood pressure and potassium monitoring and is not FDA-approved for this indication.

What is established, what is plausible, and what is not established

Established: minoxidil and finasteride/dutasteride have randomized-trial support for androgenetic alopecia; ketoconazole shampoo helps Malassezia-driven scalp disease and dandruff; iron and, less consistently, zinc deficiency contribute to diffuse shedding and correcting them helps in deficient patients; baricitinib and ritlecitinib are FDA-approved specifically for alopecia areata.

Plausible but not fully proven: scalp massage as a meaningful independent driver of hair thickness, biotin or specific supplement blends benefiting biotin-sufficient people, vitamin D supplementation reversing hair loss in people with low levels, and stress-reduction interventions producing measurable regrowth rather than simply reducing further shedding.

Not established: that any single over-the-counter cosmetic ingredient reliably reverses androgenetic alopecia without the drugs above, that post-finasteride syndrome has a confirmed mechanism or reliable incidence, and that biotin supplementation benefits people without a documented deficiency.

A decision framework for choosing where to start

Before choosing a product, sort the presentation into one of three tracks, because the tracks call for different first moves and mixing them up wastes time or, in the scarring case, causes permanent damage.

Track 1: Diffuse shedding, no pattern, no scarring, cause unclear. Start with basic labs (ferritin, TSH/free T4, 25(OH)D, zinc) before or alongside starting any product. If a deficiency is found, correct it and reassess at 3 to 6 months before adding a drug treatment. If labs are normal and shedding persists beyond 6 months, reconsider the diagnosis with a clinician rather than continuing to add supplements.

Track 2: Patterned thinning (temple/crown recession in men, crown thinning with preserved frontal hairline in women) consistent with androgenetic alopecia. Topical minoxidil is reasonable to start immediately. Finasteride (men) or, off-label, spironolactone or oral minoxidil (women of non-childbearing potential) are reasonable additions after discussing risks with a prescriber. Reassess at 6 to 12 months; PRP is a reasonable addition for partial responders, not a substitute for the above.

Track 3: Patchy loss, scarring, pustules, or scalp pain. Do not start a cosmetic or over-the-counter treatment first. See a dermatologist for exam and likely biopsy before applying anything, because scarring alopecias and infections need a specific diagnosis and, often, immunosuppressive or antimicrobial treatment rather than minoxidil or finasteride, and delay can mean permanent follicle loss.

The failure mode this framework is built to prevent is applying an androgenetic-alopecia treatment plan to a scarring or infectious presentation, which can burn months of the window when treatment would still have preserved the follicle.

Frequently asked questions

References

• Amaranthus Extract Promotes Healthy Follicles and Anagen Hair Density, a Randomized Placebo-Controlled, Double-Blinded Study (2025): https://pubmed.ncbi.nlm.nih.gov/40765496/
• Photobiomodulation Therapy in the Prevention of Chemotherapy-Induced Alopecia in Breast Cancer Patients: a Randomized Controlled Trial (2025): https://pubmed.ncbi.nlm.nih.gov/40705170/

Other claims in this article reference established clinical knowledge about minoxidil, finasteride, dutasteride, ketoconazole shampoo, PRP, and JAK inhibitors for alopecia areata. The specific trial citations, effect sizes, and journal references originally attached to those claims could not be verified against the papers they were supposedly drawn from and have been removed rather than repeated; an editor should attach verified primary sources (FDA labels, guideline documents, or specific trial DOIs) before publication where a precise number is desired.